# Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

> **NCT00005949** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** gp100:209-217(210M) peptide vaccine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00005949
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005949, "Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*